ClinicalTrials.gg
Status unknownNCT05197933Updated Jan 20, 2022

Safety of Laparoscopic Resection for Gastrointestinal Stromal Tumor on Unfavorable Anatomic Site of Stomach

An interventional study of Laparoscopic resection in Gastrointestinal Stromal Tumors, sponsored by RenJi Hospital. Status unknown at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-01-20.

Sponsored by RenJi Hospital · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jan 2022), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 11 months after the study started (first participant enrolled Oct 2020, registered Sep 2021).
Phase
Not applicable
Study type
Interventional
Enrollment
182
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The aim of this trial is to evaluate the safety of laparoscopic resection for GIST whose diameter is ≥2cm and ≤5cm at unfavorable anatomic sites of stomach.

Read the detailed description

The aim of this trial is to evaluate the safety of laparoscopic resection for GIST whose diameter is ≥2cm and ≤5cm at unfavorable anatomic sites of stomach. Unfavorable anatomic sites are defined by soft tissue sarcoma, NCCN Clinical Practice Guidelines in Oncology (version 2. 2018). The defined laparoscopy unfavorable sites including the anatomic sites of stomach other than greater curvature and front wall, including the less curvature, the posterior wall, and adjacent to cardia and pylorus.

02

Conditions studied

  • Gastrointestinal Stromal Tumors

Keywords

  • Gastrointestinal Stromal Tumors
  • Unfavorable Anatomic Site of Stomach
  • Laparoscopic Resection
03

In context

Gastrointestinal Stromal Tumors

345 studies on the registry are indexed under Gastrointestinal Stromal Tumors; 60 are open to participants now.

This study's planned enrollment of 182 is above the median of 50 across 253 interventional studies indexed under Gastrointestinal Stromal Tumors.

Browse Gastrointestinal Stromal Tumors studies →

Lead sponsor

RenJi Hospital is the lead sponsor of 550 studies on the registry; 248 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age from over 18 to under 75 years;
  • Gastrointestinal stromal tumor at unfavorable anatomic sites of stomach preoperatively confirmed by endoscopy, ultrasound endoscopy, CT or MRI;
  • Diameter of tumor size is ≥2cm and ≤5cm confirmed by contrast CT or MRI;
  • Patients whose tumor is resectable by laparoscopic technique at preoperative assessment;
  • No evidence of distant metastasis and tumor invading nearby organs at preoperative assessment;
  • Performance status of 0 or 1 on ECOG (Eastern Cooperative Oncology Group) scale;
  • ASA (American Society of Anesthesiology) score I, II, or III;
  • Written informed consent.

Exclusion criteria

Exclusion Criteria:

  • Women during pregnancy or breast-feeding;
  • Severe mental disorder;
  • History of previous upper abdominal surgery (except laparoscopic cholecystectomy);
  • History of other malignant disease within the past five years;
  • History of previous neoadjuvant imatinib therapy;
  • History of unstable angina or myocardial infarction within the past six months;
  • History of cerebrovascular accident within the past six months;
  • History of continuous systematic administration of corticosteroids within the past month;
  • Requirement of simultaneous surgery for other disease;
  • Emergency surgery due to complication (bleeding, obstruction or perforation) caused by gastrointestinal stromal tumor;
  • FEV1\<50% of predicted value;
  • Patients with GIST locates at favorable anatomic sites detected by contrast CT, MRI or ultrasound endoscopy at preoperative assessment;
  • Patients with GIST diameter\<2cm or>5cm detected by contrast CT or MRI;
  • Presence of distant metastasis or tumor invading nearby organs at preoperative assessment.

Withdrawal Criteria:

  • Patients postoperatively confirmed as non-GIST case by pathology (These cases are enrolled in safe group for future statistic analysis);
  • GIST at unfavorable anatomic site diagnosed before operation, while GIST at favorable anatomic site determined by intraoperative exploration;
  • Patients confirmed as tumor rupture , metastasis or invading nearby organs intraoperately;
  • Patients requiring simultaneous surgical treatment of other diseases;
  • Sudden severe complications during the perioperative period (intolerable surgery or anesthesia), which renders it unsuitable or unfeasible to implement the study treatment protocol as scheduled;
  • Patients confirmed to require emergency surgery by attending physicians due to changes in the patient's condition after inclusion in this study;
  • Patients who voluntarily quit or discontinue treatment for personal reasons at any stage after inclusion in this study;
  • Treatment implemented is proven to violate study protocol.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
182 participants (estimated)

Study arms

  • Experimental
    Laparoscopic resection

    laparoscopic resection for GIST at unfavorable anatomic sites of stomach

    Procedure: Laparoscopic resection

Interventions

  • ProcedureLaparoscopic resection

    Laparoscopic resection for GIST at unfavorable anatomic site of stomach will be conducted

06

What researchers measure

Primary outcomes

  1. 3-year disease-free survival rate (DFS)

    The number of patients with DFS \> 3 years was used as the numerator and the number of all patients was used as the denominator to calculate the ratio value.

    Time frame: until the date of first documented progression, assessed up to 3 years

Secondary outcomes

  1. Success rate of laparoscopic surgery

    The proportion value will be calculated for the number of patients receiving laparoscopic local resection for GIST locating at unfavorable sites of stomach and meet the following 4 criteria as the numerator and the number of all patient undergo surgical treatment (laparoscopic surgery/laparotomy) as the denominator. Definition of successful laparoscopic resection: 。① Resection is completed by total laparoscopy (extra auxiliary incision is not required. Tumor is extracted through the extended trocar incision);②Tumor is completely resected without rupture which complys with the principle of tumor isolation;③No conversion from laparoscopy to laparotomy due to incidences that laparascopy can not complete, including hemorrhage, unresectable tumor etc;④Resected margin confirmed to be negative by postoperative pathology. All the previous 4 criteria have to be achieved simultaneously to be considered a complete laparoscopic surgery.

    Time frame: postoperative 15 days

  2. Rate of intraoperative complication

    The proportion value will be calculated for the number of patients with any intraoperative complication as the numerator and the number of all patients undergoing surgical treatment (laparoscopic surgery/laparotomy) as the denominator.

    Time frame: intraoperative time

  3. Rate of Postoperative complication

    The proportion value will be calculated for the number of patients with any postoperative complication as the numerator and the number of all patients undergoing surgical treatment (laparoscopic surgery/laparotomy) as the denominator.

    Time frame: postoperative 30 days, or the discharge day if hospitalization>30 days

  4. 3-year overall survival rate (OS)

    The number of patients with OS \> 3 years was used as the numerator and the number of all patients was used as the denominator to calculate the ratio value.

    Time frame: until the date of first documented progression, assessed up to 3 years

  5. Postoperative recovery course(Time to start off-bed activities, bowel function, to restore liquid food and semi-liquid food)

    Time to start off-bed activities, bowel function, to restore liquid food and semi-liquid food * Starting from the postoperative day 1 to the first postoperative discharge, within the initial recognition of the earliest time for off-bed activities, bowel function (flatulence/bowel movement), to restoration of fluid/semi-fluid diet; records are made hourly. * Flatulence/bowel movement on the day of surgery is excluded. * In case of no off-bed activities/flatulence/bowel movement/restoration of liquid/semi-liquid diet before the first postoperative discharge, the discharge time should be recorded as the time of off-bed activities/flatulence/bowel movement/restoration of liquid/semi-liquid diet. * The initial time of off-bed activities/flatulence/bowel movement/restoration of liquid/semi-liquid diet is per patient report.

    Time frame: postoperative 30 days, or the discharge day if hospitalization>30 days

  6. Postoperative recovery course(Highest Body Temperature)

    Highest Body Temperature • The highest body temperature starting from postoperative day 1 up to day 3 should be measured at least three times a day.

    Time frame: postoperative 3 days

07

Study locations

1 of 1 sites recruiting
  • Renji hospital
    Shanghai, Shanghai Municipality 200127, China
    Recruiting
08

References and documents

Study documents

  • Protocol, analysis plan and consent form · Jul 1, 2021

Documents are hosted by the registry — open the source record to download them.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 20, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05197933
Lead sponsor
RenJi Hospital
Responsible party
Hui Cao (Professor, RenJi Hospital) — Principal investigator
First posted
Jan 20, 2022
Start date
Oct 1, 2020
Primary completion
Sep 30, 2025 (estimated)
Completion
Sep 30, 2025 (estimated)
Last update
Jan 20, 2022

Study contacts

Hui Cao, Professor
Contact
caohuishcn@hotmail.com
13918141425
Hui Cao, Professor
study chair · RenJi Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion